Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 17c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.57 +0.88%
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
HOVR, VFS, PGR, More
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.59 million versus the consensus estimate of $55.1 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $227.7 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- HIMS jumps 7% on peptide tailwind but Citi sees 17% downside from here
- Trump to issue directive to U.S. officials that seeks to control cost of diesel - Reuters
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
